ArticleFrontiers in veterinary science2024
Recombinant characteristics and pathogenicity of a novel PRRSV variant in weaned piglets derived from recombination of three clinical epidemic strains.
Article in Frontiers in veterinary science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Genetic diversity and pathogenicity of novel recombinant strains of PRRSV lineages 1.5, lineages 1.8 and lineages 8 in South China.Frontiers in cellular and infection microbiology · 2026Article
- Genetic and Respiratory Pathogenic Comparison of Two PRRSV-2 Isolates Classified as Lineage Korean A and B.Transboundary and emerging diseases · 2026Article
- Epidemiological analysis of porcine reproductive and respiratory syndrome viruses in 2020-2023 in China and the impact of serum acclimatization on production performance of sows farm.Frontiers in veterinary science · 2025Article
- Natural mutations in key NLS amino acids regulate nucleoplasmic shuttling and replication efficiency in PRRSV.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The recent emergence of PRRSV strains NADC30 and NADC34, along with their recombination with HP-PRRSV-like strains, has added complexity to PRRS control strategies on swine farms. Given the high variability and recombination potential of PRRSV, continuous monitoring of the virus's clinical epidemiology is essential for effective prevention and control. Methods: This study isolated a PRRSV variant, designated SDVD-NMG2023, from approximately 65-day-old pigs, showing a mortality rate of around 15% within the herd. The whole-genome, ORF5, and NSP2 sequences of the SDVD-NMG2023 isolate were aligned with 42 reference strains using MEGA software. Recombination analysis was performed using SimPlot software and RDP software. Pathogenicity analysis of SDVD-NMG2023 was conducted in four-week-old SPF Yorkshire piglets. Results: Phylogenetic and molecular evolutionary analyses revealed a natural recombination event involving the NADC30, NADC34, and JXA1 strains. Piglets infected with SDVD-NMG2023 exhibited mild clinical symptoms, including elevated rectal temperatures in two out of five piglets, as well as cough, mild anorexia, weight stunting, interstitial pneumonia, and thymic atrophy in all cases. Discussion: The findings indicate that the novel crossbred PRRSV isolate SDVD-NMG2023, derived from three prevalent clinical strains, may induce more unusual clinical presentations compared to those associated with HP-PRRS, albeit still impacting the health of the herd by causing immunosuppression. This study provides critical insights into the emergence of multi-strain PRRSV recombination, particularly between NADC30/34-like and HP-PRRSV-like strains, supporting a more strategic and comprehensive approach to PRRS prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.